Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
tLGm0JEu3212FDFk
